Results 1 to 10 of about 1,557 (103)
No Benefit for Idarucizumab [PDF]
Deutsches Ärzteblatt international, 2016 The review article by Lange et al. on the management of anticoagulation in the setting of endoscopic interventions provides helpful advice and pointers for routine clinical practice (1). Their assessment clashes with the available evidence in one single issue: idarucizumab has thus far not been shown to offer any benefit in terms of the safe ...
openaire +2 more sources
Cardiovascular Therapy and Prevention, 2023 The number of patients with indications for direct oral anticoagulants (DOACs) to prevent thrombotic events is steadily growing. However, in 1,1-2,2% of cases, ischemic strokes occur within DOAC therapy. In this case, DOAC use is a limitation for systemic thrombolysis, except for available reversal of anticoagulation. In order to immediately inactivate
G. R. Ramazanov +6 more
openaire +2 more sources
Idarucizumab for dabigatran reversal
Thrombosis research, 2023 Background: Idarucizumab has been approved to reverse the anticoagulant effect of dabigatran. However, there is little knowledge of the effectiveness and safety of idarucizumab in daily practice. Aims: This systematic review and meta-analysis aims to evaluate the use, effectiveness and outcomes of idarucizumab.
van der Horst, S. F. B. +6 more
openaire +1 more source
Anticoagulants: Updates on idarucizumab [PDF]
British Dental Journal, 2017 J S, Chandan, T, Thomas, H S, Baryah
openaire +2 more sources
Utilizzo di Idarucizumab [PDF]
, 2019 Utilizzo in Toscana di idarucizumab, antidoto di ...
Lombardi Niccolò +8 more
openaire
Idarucizumab Dosing in Kidney Failure [PDF]
American Journal of Kidney Diseases, 2018 Luke Yip, Jou-Fang Deng
openaire +2 more sources
Dabigatran Reversal with Idarucizumab
New England Journal of Medicine, 2017 Pollack, Charles V. +2 more
openaire +6 more sources
Anaphylaxis after Idarucizumab Infusion [PDF]
Journal of Clinical Neurology, 2017 Nam, Ki-Woong +6 more
openaire +1 more source